Today: December 15, 2017, 1:35 am
  
Business

Nightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare Conference

PR-Inside.com: 2017-12-07 12:33:01

LEXINGTON, Mass. and LONDON, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company will participate in a fireside chat at the BMO Capital Markets Prescriptions for Success Healthcare Conference on Thursday, Dec. 14, 2017 at 9:00 a.m. ET in New York City.

To access the live webcast, please visit ir.nightstartx.com. A replay of the webcast will be available on the Nightstar website for 60 days following the conference.

About Nightstar

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar's lead product candidate, NSR-REP1, is being developed as a treatment for patients with choroideremia, a rare, degenerative, genetic retinal disorder that has no current treatments and affects approximately one in every 50,000 people. Positive results from a Phase 1/2 trial of NSR-REP1 were published in The Lancet in 2014 and in The New England Journal of Medicine in 2016. Nightstar plans to commence a Phase 3 registrational trial of NSR-REP1 for choroideremia at sites in the United States, Europe and Canada in the first half of 2018. Nightstar's second product candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease that affects approximately one in every 40,000 people.

For more information about Nightstar or its clinical trials, please visit www.nightstartx.com.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to: statements about our plans to develop and commercialize our product candidates, our planned clinical trials for NSR-REP1 and NSR-RPGR, the clinical utility of our product candidates, the prevalence of patient populations for our targeted indications, and the utility of prior preclinical and clinical data in determining future clinical results . These forward-looking statements are based on management's current expectations of future events and are subject to a number of involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risks and uncertainties set forth in the "Risk Factors" section of our prospectus filed pursuant to Rule 424(b)(4) under the U.S. Securities Act of 1933, as amended, on September 28, 2017, and subsequent reports that we file with the U.S. Securities and Exchange Commission. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Contact:

Senthil Sundaram, Chief Financial Officer
investors@nightstartx.com 

Alicia Davis, THRUST IR
910-620-3302
alicia@thrustir.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nightstar Therapeutics via Globenewswire




# 792 Words
Related Articles
More From The Author
Energean Signs Further Gas Sales Contracts and [..]
Energean Oil & Gas (“Energean” or “the Company”) is pleased to announce that Energean Israel has signed further Gas [..]
Neustar Launches Next Generation DDoS Defense Network: [..]
Neustar : It is the latest wave of the company’s purpose-built DDoS mitigation solution designed to meet the security requirements [..]
Nasdaq SMARTS Receives FOW Award for Best [..]
The accolade was granted for its unique 'Depth View' product development NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ), [..]
Case Study: How BRIDGE Increased a Client’s [..]
To sustain growth and increase organic traffic in Europe, BRIDGE partnered with Pizza Hut to launch a vast project to [..]
Tricentis and Spectar Unveil the World’s First [..]
Tricentis APAC (Pty) Ltd in association with Spectar Group now offers a convenient product solution to all SAP customers, called [..]
 
More From Business
Cirtek Holdings Philippines Corp Holds Its First-Ever [..]
SAN FRANCISCO, CA, Dec 8, 2017 - (ACN Newswire) - All-Asia institutional equities broker Decker & Co. hosted Cirtek Holdings [..]
Business of Intellectual Property (BIP Asia) Forum [..]
Industry Experts Gather in Hong Kong to Promote IP and Innovation HONG KONG, Dec 7, 2017 - (ACN Newswire) - [..]
Select the best flower and present it [..]
You can send flowers to your friends and relatives within the city. You can also present flowers to your beloved [..]
European Tech Startup LivingPackets Launches Pilot International [..]
A game-changing international delivery startup LivingPackets has secured support of the five-star St Pancras Renaissance Hotel, [..]
Experienced Business Coaches Launch “Business Wingmen” Podcast [..]
SANTA ANA, Calif., - November 27, 2017- Two prominent Orange County business coaches announced the formation and launch of [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.